Lalwani Nikhil's Form 4 filing
Ani Pharmaceuticals Inc (ANIP) · filed Aug 14, 2025
- Accession no.
- 0001822629-25-000010
- Filed
- Aug 14, 2025
- Trade date
- Aug 12, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $4.89M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lalwani NikhilCIK 0001822629 | Director, Officer (PRESIDENT & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 12, 2025 | Common Stock | SSaleDisposed | −56,960 | $85.93F1 | −$4,894,572.8 | 411,219 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The shares were sold in multiple trades at prices ranging from $84.40 to $87.47. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.